Platelet activating factor

Platelet activating factor is a lipid of Glycerophospholipids (GP) class. Platelet activating factor is associated with abnormalities such as Atherosclerosis, Acute cholecystitis without calculus, Cholecystitis, Colitis and Cholecystitis, Acute. The involved functions are known as Cell Survival, Metabolic Inhibition, lipid oxidation, Apoptosis and Oxidation. Platelet activating factor often locates in soluble, Cellular Membrane, Smooth muscle (tissue), Intima and Tissue specimen. The associated genes with Platelet activating factor are apolipoprotein A-I Milano, Homologous Gene, TSPO gene, HBEGF gene and SLC33A1 gene. The related lipids are Hydroxycholesterols, Liposomes, 25-hydroxycholesterol, Lysophosphatidylcholines and Lipopolysaccharides. The related experimental models are Knock-out, Mouse Model and Transgenic Model.

Cross Reference

Introduction

To understand associated biological information of Platelet activating factor, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with Platelet activating factor?

Platelet activating factor is suspected in Ischemia, Pleurisy, Atherosclerosis, Inflammatory disorder, Retinal Diseases, Diabetes and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with Platelet activating factor

MeSH term MeSH ID Detail
Body Weight D001835 333 associated lipids
Lung Neoplasms D008175 171 associated lipids
Adenocarcinoma D000230 166 associated lipids
Colonic Neoplasms D003110 161 associated lipids
Edema D004487 152 associated lipids
Carcinoma, Hepatocellular D006528 140 associated lipids
Hemolysis D006461 131 associated lipids
Cell Transformation, Neoplastic D002471 126 associated lipids
Inflammation D007249 119 associated lipids
Hypertension D006973 115 associated lipids
Glioma D005910 112 associated lipids
Weight Gain D015430 101 associated lipids
Hypercholesterolemia D006937 91 associated lipids
Diabetes Mellitus D003920 90 associated lipids
Brain Ischemia D002545 89 associated lipids
Diabetes Mellitus, Type 2 D003924 87 associated lipids
Seizures D012640 87 associated lipids
Arteriosclerosis D001161 86 associated lipids
Atherosclerosis D050197 85 associated lipids
Pancreatic Neoplasms D010190 77 associated lipids
Alzheimer Disease D000544 76 associated lipids
Stomach Ulcer D013276 75 associated lipids
Leukemia D007938 74 associated lipids
Coronary Disease D003327 70 associated lipids
Colitis D003092 69 associated lipids
Melanoma D008545 69 associated lipids
Liver Cirrhosis D008103 67 associated lipids
Mammary Neoplasms, Experimental D008325 67 associated lipids
Neuroblastoma D009447 66 associated lipids
Cystic Fibrosis D003550 65 associated lipids
Reperfusion Injury D015427 65 associated lipids
Pain D010146 64 associated lipids
Dermatitis, Contact D003877 59 associated lipids
Diabetes Mellitus, Type 1 D003922 56 associated lipids
Weight Loss D015431 56 associated lipids
Nerve Degeneration D009410 53 associated lipids
Parkinson Disease D010300 53 associated lipids
Asthma D001249 52 associated lipids
Kidney Failure, Chronic D007676 51 associated lipids
Osteosarcoma D012516 50 associated lipids
Thrombosis D013927 49 associated lipids
Coronary Artery Disease D003324 47 associated lipids
Psoriasis D011565 47 associated lipids
Metabolism, Inborn Errors D008661 46 associated lipids
Metabolic Syndrome D024821 44 associated lipids
Hypersensitivity, Delayed D006968 43 associated lipids
Lupus Erythematosus, Systemic D008180 43 associated lipids
Hyperalgesia D006930 42 associated lipids
Ischemic Attack, Transient D002546 42 associated lipids
Leukemia, Experimental D007942 42 associated lipids
Arrhythmias, Cardiac D001145 42 associated lipids
Leukemia, Erythroblastic, Acute D004915 41 associated lipids
Arthritis D001168 41 associated lipids
Hypotension D007022 41 associated lipids
Neovascularization, Pathologic D009389 39 associated lipids
Diabetic Retinopathy D003930 39 associated lipids
Zellweger Syndrome D015211 39 associated lipids
Peritonitis D010538 38 associated lipids
Nervous System Diseases D009422 37 associated lipids
Lung Diseases D008171 37 associated lipids
Liver Cirrhosis, Experimental D008106 36 associated lipids
Fever D005334 35 associated lipids
Glomerulonephritis D005921 35 associated lipids
Anaphylaxis D000707 35 associated lipids
Epilepsy D004827 35 associated lipids
Infarction, Middle Cerebral Artery D020244 35 associated lipids
Spinal Cord Injuries D013119 34 associated lipids
Anemia, Sickle Cell D000755 34 associated lipids
Burns D002056 34 associated lipids
Acute Kidney Injury D058186 34 associated lipids
Acute Lung Injury D055371 33 associated lipids
Uremia D014511 33 associated lipids
Memory Disorders D008569 33 associated lipids
Thyroid Neoplasms D013964 33 associated lipids
Stroke D020521 32 associated lipids
Neurodegenerative Diseases D019636 32 associated lipids
Hypertension, Pulmonary D006976 32 associated lipids
Cardiomegaly D006332 31 associated lipids
Proteinuria D011507 30 associated lipids
Endometrial Neoplasms D016889 30 associated lipids
Vitamin E Deficiency D014811 29 associated lipids
Neuralgia D009437 28 associated lipids
Ventricular Remodeling D020257 28 associated lipids
Mammary Neoplasms, Animal D015674 27 associated lipids
Gastrointestinal Hemorrhage D006471 27 associated lipids
Endotoxemia D019446 27 associated lipids
Angina Pectoris D000787 27 associated lipids
Hyperinsulinism D006946 27 associated lipids
Brain Diseases D001927 27 associated lipids
Gastritis D005756 27 associated lipids
Encephalomyelitis, Autoimmune, Experimental D004681 26 associated lipids
Nasal Polyps D009298 26 associated lipids
Pseudomonas Infections D011552 25 associated lipids
Ascites D001201 25 associated lipids
Cerebrovascular Disorders D002561 25 associated lipids
Leukemia-Lymphoma, Adult T-Cell D015459 25 associated lipids
Pulmonary Fibrosis D011658 24 associated lipids
Colitis, Ulcerative D003093 24 associated lipids
Arthritis, Experimental D001169 24 associated lipids
Cardiovascular Diseases D002318 24 associated lipids
Per page 10 20 50 100 | Total 288

PubChem Associated disorders and diseases

What pathways are associated with Platelet activating factor

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with Platelet activating factor?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with Platelet activating factor?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with Platelet activating factor?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with Platelet activating factor?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with Platelet activating factor?

Knock-out

Knock-out are used in the study 'A cardioprotective role for platelet-activating factor through NOS-dependent S-nitrosylation.' (Leary PJ et al., 2008).

Mouse Model

Mouse Model are used in the study 'A regulatory role of LPCAT1 in the synthesis of inflammatory lipids, PAF and LPC, in the retina of diabetic mice.' (Cheng L et al., 2009).

Transgenic Model

Transgenic Model are used in the study 'Heterogeneity in the sn-1 carbon chain of platelet-activating factor glycerophospholipids determines pro- or anti-apoptotic signaling in primary neurons.' (Ryan SD et al., 2008).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with Platelet activating factor

Download all related citations
Per page 10 20 50 100 | Total 8526
Authors Title Published Journal PubMed Link
Mueller HW et al. 1-O-alkyl-linked glycerophospholipids of human neutrophils: distribution of arachidonate and other acyl residues in the ether-linked and diacyl species. 1984 J. Lipid Res. pmid:6427378
O'Flaherty JT et al. Diacylglycerols enhance human neutrophil degranulation responses: relevancy to a multiple mediator hypothesis of cell function. 1984 Biochem. Biophys. Res. Commun. pmid:6433920
Mendlovic F et al. Possible involvement of cyclooxygenase products in the actions of platelet-activating factor and of lipoxygenase products in the vascular effects of epinephrine in perfused rat liver. 1984 Biochem. Biophys. Res. Commun. pmid:6435614
Fouque F and Vargaftig BB Triggering by Paf-acether and adrenaline of cyclo-oxygenase-independent platelet aggregation. 1984 Br. J. Pharmacol. pmid:6439269
Karlsson G and Pipkorn U Effect of disodium chromoglycate on changes in nasal airway resistance induced by platelet activating factor. 1984 Eur. J. Clin. Pharmacol. pmid:6439565
Sänze JU et al. On the nature of the vasoreactivity depressing factor (VDF) in inflammation and anaphylaxis in the rat and mouse. 1984 Biomed. Biochim. Acta pmid:6440544
Handley DA et al. Effect of platelet activating factor on endothelial permeability to plasma macromolecules. 1984 Immunopharmacology pmid:6083990
Camussi G et al. Effect of platelet activating factor on guinea-pig papillary muscle. 1984 Experientia pmid:6086382
Sills RH Thrombotic thrombocytopenic purpura. I. Pathophysiology and clinical manifestations. 1984 Am J Pediatr Hematol Oncol pmid:6442830
Lartigue-Mattei C et al. Pharmacokinetic study of 3H-labelled PAF-acether II. Comparison with 3H-labelled lyso-PAF-acether after intravenous administration in the rabbit and protein binding. 1984 Agents Actions pmid:6532184
Kulikov VI et al. [Incorporation of 1-0-alkyl-2-acetyl-sn-glycerol-3-phosphocholine into human plasma lipoproteins in vitro. Effect of the lecithin:cholesterol acyltransferase activity of plasma]. 1984 Biokhimiia pmid:6542803
Smith RJ et al. Stimulation of the human neutrophil superoxide anion-generating system with 1-O-hexadecyl/octadecyl-2-acetyl-sn-glyceryl-3- phosphorylcholine. 1984 Biochem. Pharmacol. pmid:6324816
Buxton DB et al. Stimulation of hepatic glycogenolysis by acetylglyceryl ether phosphorylcholine. 1984 J. Biol. Chem. pmid:6693418
Sakamoto H et al. Stimulation of leukocyte phagocytic activity by the platelet release reaction. 1984 Pathology pmid:6462776
Shukla SD and Hanahan DJ Acetylglyceryl ether phosphorylcholine (AGEPC; platelet-activating factor)-induced stimulation of rabbit platelets: correlation between phosphatidic acid level, 45Ca2+ uptake, and [3H]serotonin secretion. 1984 Arch. Biochem. Biophys. pmid:6465886
Doebber TW et al. Platelet activating factor intravenous infusion in rats stimulates vascular lysosomal hydrolase secretion independent of blood neutrophils. 1984 Biochem. Biophys. Res. Commun. pmid:6517949
Heinrich J and Zimmermann RE Compound 48/80 is a potent inhibitor of human platelet aggregation antagonizing the calmodulin-dependent platelet reaction in vitro. 1984 Thromb. Res. pmid:6523451
Oxholm P et al. Lack of evidence for human lymphokines with thrombocyte aggregating activity. An in vitro study. 1984 Allergy pmid:6528957
Hwang SB et al. Effects of nonsteroid antiinflammatory drugs on the specific binding of platelet activating factor to membrane preparations of rabbit platelets. 1984 Thromb. Res. pmid:6429890
Colditz IG and Movat HZ Kinetics of neutrophil accumulation in acute inflammatory lesions induced by chemotaxins and chemotaxinigens. 1984 J. Immunol. pmid:6470487
Patterson R et al. Airway responses to sequential challenges with platelet-activating factor and leukotriene D4 in rhesus monkeys. 1984 J. Lab. Clin. Med. pmid:6470563
Pinckard RN et al. Molecular heterogeneity of platelet-activating factor produced by stimulated human polymorphonuclear leukocytes. 1984 Biochem. Biophys. Res. Commun. pmid:6743335
Feuerstein G et al. Effect of platelet-activating factor on coronary circulation of the domestic pig. 1984 Am. J. Physiol. pmid:6703081
Pipkorn U et al. Effect of platelet activating factor on the human nasal mucosa. 1984 Allergy pmid:6703263
Lüthje J and Ogilvie A Diadenosine triphosphate (Ap3A) mediates human platelet aggregation by liberation of ADP. 1984 Biochem. Biophys. Res. Commun. pmid:6704102
Clare KA and Scrutton MC The role of Ca2+ uptake in the response of human platelets to adrenaline and to 1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine (platelet-activating factor). 1984 Eur. J. Biochem. pmid:6705791
Kumar R et al. A facile route to semi-synthesis of acetyl glycerylether phosphoethanolamine and its choline analogue. 1984 J. Lipid Res. pmid:6707528
Archer CB et al. Synergistic interaction between prostaglandins and PAF-acether in experimental animals and man. 1984 Prostaglandins pmid:6203139
Camussi G et al. Platelet-activating factor-induced loss of glomerular anionic charges. 1984 Kidney Int. pmid:6374251
Schlondorff D et al. Effect of platelet-activating factor and serum-treated zymosan on prostaglandin E2 synthesis, arachidonic acid release, and contraction of cultured rat mesangial cells. 1984 J. Clin. Invest. pmid:6423667
Vargaftig BB et al. [Platelet aggregation and PAF-acether. Pharmacologic interference]. 1984 J Pharmacol pmid:6374298
Ito S et al. Hyperacute renal allograft rejection in the rabbit. The role of platelet-activating factor and of cationic proteins derived from polymorphonuclear leukocytes and from platelets. 1984 Lab. Invest. pmid:6379289
Bult H et al. Complement derived factors and prostacyclin formation by rabbit isolated peritoneum and cultured mesothelial cells. 1984 Agents Actions Suppl. pmid:6382974
Hechtman HB et al. Role of humoral mediators in adult respiratory distress syndrome. 1984 Chest pmid:6383742
Kelton JG et al. The detection of a platelet-agglutinating factor in thrombotic thrombocytopenic purpura. 1984 Ann. Intern. Med. pmid:6333196
Bussolino F et al. Release of platelet-activating factor (PAF)-like material from human lymphoid cell lines. 1984 Exp. Hematol. pmid:6333353
Wodzinowska B and Krajewski T [Role of blood platelets and their membrane in the process of hemostasis]. 1984 Jan-Feb Postepy Hig Med Dosw pmid:6093087
Vemulapalli S et al. Cardiovascular and renal action of platelet-activating factor in anesthetized dogs. 1984 Jul-Aug Hypertension pmid:6378787
Cox CP et al. VIP elevates platelet cyclic AMP (cAMP) levels and inhibits in vitro platelet activation induced by platelet-activating factor (PAF). 1984 Mar-Apr Peptides pmid:6206481
Shen TY et al. The isolation and characterization of kadsurenone from haifenteng (Piper futokadsura) as an orally active specific receptor antagonist of platelet-activating factor. 1985 Int J Tissue React pmid:2997065
Sánchez Crespo M et al. Synthesis of platelet-activating factor from human polymorphonuclear leukocytes: regulation and pharmacological approaches. 1985 Int J Tissue React pmid:2997066
Tamargo J et al. Electrophysiological effects of platelet-activating factor (PAF-acether) in guinea-pig papillary muscles. 1985 Eur. J. Pharmacol. pmid:3996472
Touqui L et al. 1-O-alkyl-2-acyl-sn-glycero-3-phosphorylcholine is the precursor of platelet-activating factor in stimulated rabbit platelets. Evidence for an alkylacetyl-glycerophosphorylcholine cycle. 1985 Biochim. Biophys. Acta pmid:3967037
Ardaillou N et al. Vasoconstrictor-evoked prostaglandin synthesis in cultured human mesangial cells. 1985 Am. J. Physiol. pmid:3918460
Lee TC Biosynthesis of platelet activating factor. Substrate specificity of 1-alkyl-2-lyso-sn-glycero-3-phosphocholine:acetyl-CoA acetyltransferase in rat spleen microsomes. 1985 J. Biol. Chem. pmid:4030776
Wissner A et al. Analogues of platelet activating factor (PAF). 2. Some modifications of the glycerine backbone. 1985 J. Med. Chem. pmid:4032422
Pritchard PH et al. The degradation of platelet-activating factor in the plasma of a patient with familial high density lipoprotein deficiency (Tangier disease). 1985 Blood pmid:4063532
Oda M et al. Molecular species of platelet-activating factor generated by human neutrophils challenged with ionophore A23187. 1985 J. Immunol. pmid:3917470
O'Neill C et al. Maternal recognition of pregnancy prior to implantation: methods for monitoring embryonic viability in vitro and in vivo. 1985 Ann. N. Y. Acad. Sci. pmid:2409860
Sage SO and Rink TJ Inhibition by forskolin of cytosolic calcium rise, shape change and aggregation in quin2-loaded human platelets. 1985 FEBS Lett. pmid:2410292